Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OncoPep has signed an exclusive, worldwide license agreement with Dana-Farber Cancer Institute for a multi-peptide therapeutic cancer vaccine technology.
Subscribe to our email newsletter
Financial terms of the agreement have not been disclosed.
PVX-410, the first vaccine developed from this technology, is designed to target multiple myeloma cells.
A Phase 1/2a trial, in which PVX-410 will be studied in patients with smoldering multiple myeloma, is planned for 2012.
PVX-410 is composed of four proprietary, synthetic peptides to form a therapeutic cancer vaccine, which is designed to target specific antigens found on the surface of multiple myeloma cells.
PVX-410 has demonstrated the ability to stimulate a strong immune response against multiple myeloma cell lines and patient cells in vitro.
OncoPep CEO Doris Peterkin said the license with Dana-Farber provides them with an underlying technology that will give the company the opportunity to develop additional therapeutic vaccine candidates in the future.